前列腺粉碎器临床结局与效率的系统综述与Meta分析
该系统综述纳入22项研究共5980例患者,评估不同前列腺粉碎器在BPH剜除术中的效率与安全性。Piranha粉碎效率为7.80 g/min,VersaCut为4.70 g/min;经体积校正后VersaCut效率显著低于Piranha,且膀胱黏膜损伤风险更高。摆动刀片系统(尤其Piranha)效率更高、安全性更好,大体积前列腺差异更明显。
要点
- Piranha粉碎效率7.80 g/min,VersaCut为4.70 g/min。
- VersaCut较Piranha效率低2.75 g/min,>70 mL前列腺差异更大。
- VersaCut膀胱黏膜损伤风险是Piranha的3.22倍。
核心结论
- 摆动刀片系统(尤其Piranha)比往复刀片设备粉碎效率更高且安全性更好。
- 大体积前列腺中不同粉碎器的性能差异最大。
研究设计与样本
- 纳入22项研究共5980例患者,多数接受钬激光前列腺剜除术。
主要发现
- 未调整加权平均粉碎效率:Piranha 7.80 g/min(95%CI 6.26-9.34),VersaCut 4.70 g/min(95%CI 3.61-5.79),DrillCut 5.90 g/min(95%CI 3.16-8.64),MultiCut 9.59 g/min(95%CI 4.78-14.39)。
- 体积校正Meta回归以Piranha为参照,VersaCut效率低2.75 g/min(95%CI -4.58至-0.92,P=0.003),前列腺>70 mL时差异达-4.34 g/min。
- 膀胱黏膜损伤是最常见并发症但各设备均较罕见;VersaCut较Piranha风险比3.22(95%CI 1.81-5.71),异质性低。
关键数值与推荐
- 主要结局为粉碎效率(g/min),次要结局包括术中并发症、设备故障和成本(当可获取时)。
- 偏倚风险评估采用ROBINS-I、RoB 2工具和EAU病例系列标准。
临床怎么用
- 选择粉碎器时可优先考虑摆动刀片系统如Piranha,尤其对大体积前列腺。
- 使用VersaCut时需注意膀胱黏膜损伤风险较高且效率较低。
局限性
- 多数研究为观察性设计,部分设备研究数量较少。
- 成本数据仅在部分研究中可获取。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To systematically evaluate the efficiency and safety of different prostate morcellators used during prostate enucleation for benign prostatic hyperplasia (BPH). METHODS: A systematic review was performed according to the Preferred Reporting Items for Systematic Review and Meta-analyses guidelines. PubMed/Medline, Scopus, and Web of Science were searched for studies published between October 2012 and May 2025. Studies reporting clinical outcomes of morcellators used during prostate enucleation were included. Primary outcome was morcellation efficiency (g/min). Secondary outcomes included intraoperative complications, device malfunction, and cost when available. Risk of bias (RoB) was assessed using the Risk Of Bias In Non-randomised Studies of Interventions (ROBINS-I), RoB 2 tool, and European Association of Urology case-series criteria. Random-effects meta-analyses and multilevel meta-regression adjusted for prostate volume were conducted. RESULTS: A total of 22 studies comprising 5980 patients were included, most undergoing holmium laser enucleation of the prostate. The most frequently evaluated devices were the Piranha™ (Richard Wolf GmbH, Knittlingen, Germany) and Lumenis VersaCut™ (Lumenis Ltd., Yokneam, Israel; 12 and 13 studies, respectively), followed by DrillCut™ (Karl Storz SE & Co. KG, Tuttlingen, Germany), MultiCut™ (Asclepion Laser Technologies GmbH, Jena, Germany), and Cyber Blade™ (Quanta System SpA, Milan, Italy) systems. Unadjusted weighted mean morcellation efficiency was 7.80 g/min (95% confidence interval [CI] 6.26-9.34 g/min) for Piranha, 4.70 g/min (95% CI 3.61-5.79 g/min) for VersaCut, 5.90 g/min (95% CI 3.16-8.64 g/min) for DrillCut, and 9.59 g/min (95% CI 4.78-14.39 g/min) for MultiCut. In volume-adjusted meta-regression using Piranha as reference, VersaCut remained significantly less efficient (-2.75 g/min; 95% CI -4.58 to -0.92 g/min; P = 0.003), with an even greater difference in prostates >70 mL (-4.34 g/min). Bladder mucosal injury was the most frequently reported complication; however, relatively rare across all devices. Meta-analysis demonstrated a significantly higher risk with VersaCut compared to Piranha (risk ratio 3.22, 95% CI 1.81-5.71), with low heterogeneity. CONCLUSION: This systematic review provides a contemporary clinical benchmark of the efficiency and safety of currently available prostate morcellators. Oscillating blade systems, particularly the Piranha morcellator, demonstrated higher morcellation efficiency and a more favourable safety profile than reciprocating blade devices, with the largest performance differences observed in patients with larger prostates.
引用
- Kutchukian S, Scilipoti P, Abi Abdallah M, et al. Prostate morcellation devices: a systematic review and meta-analysis of clinical outcomes and efficiency. BJU Int. 2026. PMID: 42420210. doi:10.1111/bju.70362
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。